Managing NAFLD/NASH in People with T2 Diabetes: Disease Burden · Diagnosis · Current/Emerging Armamentarium

(5:30 a.m.-5:45 a.m.—Registration & Breakfast/5:45 a.m.-7:45 a.m.—Program)

This CME/CEU/CPE symposium will focus on risk of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) & associated liver fibrosis in people with T2 diabetes, and includes summaries of ADA and other Guidelines on screening, diagnosis, current treatment practice, as well as presentation of novel Phase III data. Clinical Cases will illustrate management of patients with mild/moderate/severe NASH, and your queries will be addressed during a robust Q&A session.